Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab, Bevacizumab, and Paclitaxel in HER2+ Gastric Cancer
NCT05640830Phase 2Recruiting
- Sponsor
- Kangbuk Samsung Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, bevacizumab and paclitaxel in gastric cancer (GC), sponsored by Kangbuk Samsung Hospital. Primary endpoint: Progression-free survival up to 36 months. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05640830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640830.